Updated NCCN guidelines for multiple myeloma add dedicated recommendations for MRD testing, prefer tests that can detect one cancer cell among 1 million cells and expand when testing should occur.
|Articles|May 1, 2015
Jasmine Martin Discusses Oral Adherence
Author(s)Jasmine Martin
Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.
Advertisement
Jasmine Martin, Director, West Region Medical Science Liaison Team, Takeda Oncology, discusses oral adherence.
“If patients aren’t taking their drugs, then how do we know that the outcomes will be [the same as] what the clinical trial [outcomes] were?” Martin asks.
Advertisement
Related to this article
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Talvey and Darzalex combinations helped patients with relapsed multiple myeloma live longer without disease progression in the phase 3 MonumenTAL-3 trial.
Advertisement
Advertisement